552293-48-8 Usage
Molecular structure
The compound has a complex molecular structure with multiple functional groups, including a piperidinecarboxylic acid group, phenyl, trifluoromethyl, and dimethyl groups.
Ester group
The compound is a phenylmethyl ester, which means it has a carbonyl group (C=O) bonded to a phenyl group and a methyl group.
Ether group
The compound contains an ether group, which is an oxygen atom bonded to two alkyl or aryl groups, in this case, (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy and (1,1-dimethylethyloxy)carbonyl.
Hydroxyl group
The compound has a hydroxyl group (-OH) bonded to a carbon atom, specifically a hydroxymethyl group (-CH2OH).
Amino and carbonyl groups
The compound features an amino group (-NH2) and a carbonyl group (C=O) bonded to each other, forming an amide bond.
Chiral compound
The compound is chiral, meaning it has a stereocenter, which is denoted by the (2S)prefix. This indicates that the compound has a specific three-dimensional arrangement of atoms.
Substitution pattern
The piperidine ring is substituted with various functional groups, including a hydroxymethyl group, a phenyl group, and the aforementioned ester, ether, and amide groups.
Check Digit Verification of cas no
The CAS Registry Mumber 552293-48-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,5,2,2,9 and 3 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 552293-48:
(8*5)+(7*5)+(6*2)+(5*2)+(4*9)+(3*3)+(2*4)+(1*8)=158
158 % 10 = 8
So 552293-48-8 is a valid CAS Registry Number.
552293-48-8Relevant academic research and scientific papers
And as the antagonist aminopyrrolidine deriv. NK1 aminopiperidine (by machine translation)
-
Paragraph 0582-0590, (2016/10/08)
A NK 1 antagonist having the formula (I), wherein Ar 1 and Ar 2 are optionally substituted phenyl or heteroaryl, X 1 is an ether, thio or imino linkage, R 4 and R 5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
NK1 ANTAGONISTS
-
Page/Page column 89-90, (2010/02/15)
A compound having the general structure shown in Formula (I) or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symp
